BROOKLYN IMMUNOTHERAPEUTICS

Brooklyn ImmunoTherapeutics operates as a clinical-stage biopharmaceutical company. The Company discovers and develops a novel cytokine-based therapy to treat patients with cancer. Their advanced program is studying the safety and efficacy of IRX-2 in patients with head and neck cancer. In a Phase 2a clinical trial in head and neck cancer, IRX-2 demonstrated an overall survival benefit. The IRX-2 delivers hd-IL-2 and other key cytokines to potentially restore immune function in the tumor microenvironment, enabling the immune system to attack cancer cells. Brooklyn ImmunoTherapeutics serves patients and customers in the State of New York.